About Zenith Healthcare

Zenith Healthcare brings Moluzen (Molnupravir) - A New Hope in the treatment of Covid- 19.

Covid-19 has been around for more than 2 years and new variants and their lineages have been emerging continuously. We have also witnessed vaccine breakthrough infections.

With approximately 375 million cases globally and more than 5.6 million deaths, there has been significant unmet medical need for Covid-19 therapeutics. Both Monoclonal antibodies and Remdesvir have their own notable limitations.Before the approval of Molnupravir, there were no
adequate, approved oral antiviral agents for the treatment of mild to moderate Covid-19 patients.

Molnupiravir is the first oral, direct-acting antiviral which is shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

In December, 2021, US drug cleared Molnupiravir, the first antiviral Covid-19 pill, a new hope in the treatment of Covid-19. The drug was developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck. The US drug regulator
has authorized Molnupiravir for the treatment of mild-to-moderate coronavirus disease in positive tested adults and those with the high risk of hospitalization and death.

Molnupiravir works by introducing errors into the SARS-CoV-2 virus’ genetic code, which prevents the virus from further replication. As per the press release by Merck & Co, the released details indicate that Molnupiravir in its full dosage helps in drop in infection length. Shorter
infections means smaller chances of transmission or severe symptoms.
Recently, the Indian drug regulator has also approved the drug for the treatment of adult Covid-19 patients and those who have a high risk of disease progression.

Zenith Healthcare Limited, an ISO 9001:2008 & WHO-cGMP certified company, has been established since 1994. With its worldwide distribution network, Zenith healthcare has been at the forefront in upgrading its quality standards as per both National and International norms.

Zenith Healthcare has introduced Molnupiravir by the following names,
- Moluzen 200mg Capsule
- Moluzen 400mg Capsule
- Moluzen 800mg Tablet

The below table indicates the full dosage of Molnupiravir drug required for the Covid-19 treatment:
Name Oral Dosage Total Duration
Moluzen 800 mg 1 tablet every 12 hours 5 Days
Moluzen 400 mg 2 Capsules every 12 hours 5 Days
Moluzen 200 mg 4 Capsules every 12 hours 5 Days

As per the data available, Moluzen (Molnupiravir) needs no dose adjustment in patients with renal or hepatic impairment. As of now, no drug interactions are identified. It can be taken either with or without food. Also, the treatment should be initiated within 5 days of symptom onset.